Stock Analysis on Net

DexCom Inc. (NASDAQ:DXCM)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 26, 2023.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Historical Valuation Ratios (Summary)

DexCom Inc., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).


Price to Earnings (P/E) Ratio
The Price to Earnings ratio shows a trend of high variability over the examined quarters. Initially, data is unavailable up to early 2020, after which the P/E ratio declines from a peak near 228 in March 2020 to a low near 79 by March 2021. This is followed by a recovery reaching over 255 at the end of the first quarter of 2022, indicating increased investor expectations or earnings fluctuations. Subsequently, the ratio moderately declines again but remains elevated relative to initial unavailable periods, ending near 83 by the third quarter of 2023. Overall, the P/E ratio exhibits pronounced fluctuations and a generally elevated valuation multiple in recent years.
Price to Operating Profit (P/OP) Ratio
The Price to Operating Profit ratio remains relatively stable over the reporting period, with values consistently above 100, indicating that the market prices the company at a substantial premium relative to operating profit. Starting around 162 in early 2020, it shows a mild decreasing tendency to approximately 123 by the end of 2020, followed by fluctuations ranging roughly between 106 and 150 up to mid-2023. Notably, there is a downward movement approaching the later data points, ending near 62 in the third quarter of 2023, suggesting a potential compression in market valuation relative to operating profitability in recent quarters.
Price to Sales (P/S) Ratio
The Price to Sales ratio displays significant volatility, initially staying within a range of 9.5 to 12.7 in 2018. From 2019 through 2021, there is a pronounced upward trend reaching peaks above 23, indicating increasing market valuation relative to sales. However, starting in early 2022, the ratio declines to a minimum slightly above 12.7, followed by a slight recovery and then another drop to approximately 9.2 by the third quarter of 2023. This pattern suggests that after a period of premium valuation growth relative to sales, market sentiment or sales growth dynamics may have softened recently.
Price to Book Value (P/BV) Ratio
The Price to Book Value ratio demonstrates a generally elevated valuation level throughout the period, with values fluctuating mostly between 15 and 31. Early years show a rising trend from around 15.5 in the first quarter of 2018 to nearly 31 by the first quarter of 2020, suggesting increasing market valuation relative to net asset value. Subsequently, the ratio decreases somewhat but remains elevated in the range of approximately 18 to 25 through 2021. In the most recent quarters up to late 2023, there is a renewed decline reaching about 13.8, indicating a moderation in valuation relative to book value. This trend suggests a movement toward a more conservative market assessment of the company's net asset base compared with earlier periods.

Price to Earnings (P/E)

DexCom Inc., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1
Selected Financial Data (US$)
Net income (loss) (in thousands)
Earnings per share (EPS)2
Share price1, 3
Valuation Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
EPS = (Net income (loss)Q3 2023 + Net income (loss)Q2 2023 + Net income (loss)Q1 2023 + Net income (loss)Q4 2022) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

5 Click competitor name to see calculations.


Share Price
The share price displayed significant growth from March 2018 through September 2021, rising from $18.58 to a peak of $142.58. This period reflects a robust upward trend with some volatility, especially notable increases occurred in late 2019 and 2020. However, from December 2021 onwards, the share price experienced a general decline with fluctuations, dropping to $81.09 by September 2023. This suggests volatility and a downward correction in more recent quarters following the earlier strong performance.
Earnings per Share (EPS)
EPS data began in December 2018 and initially showed negative values until December 2019, where EPS was -$0.47, indicating losses. From March 2020, earnings turned positive and steadily increased, peaking at $1.37 in the last quarter of 2021. Afterward, EPS fell sharply in March 2022 to $0.40 but then showed moderate recovery and relative stability around the range of $0.5 to $0.98 until September 2023. The overall pattern suggests a transition from losses to profitability, followed by some earnings volatility in recent quarters.
Price-to-Earnings (P/E) Ratio
P/E ratios are available from March 2020 and show very high values overall, indicating that the share price was valued significantly higher than earnings throughout the period. The ratio fluctuated between approximately 79 and 255, peaking in March 2022 at 255.37 and generally trended downward after that peak to 83.11 by September 2023. The high P/E ratios reflect elevated market expectations relative to earnings, and the recent decline may indicate a reassessment towards more moderate valuation levels.
Summary of Trends
The period analyzed demonstrates a company moving from negative earnings to sustained profitability, although with some recent earnings volatility. The share price growth was strong throughout much of the timeline, with a notable peak before a downward correction. P/E ratios remained high, highlighting elevated market valuations that have somewhat normalized recently. The data overall suggests initial rapid growth and optimism, followed by a period of correction and more cautious valuation.

Price to Operating Profit (P/OP)

DexCom Inc., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1
Selected Financial Data (US$)
Operating income (loss) (in thousands)
Operating profit per share2
Share price1, 3
Valuation Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Operating profit per share = (Operating income (loss)Q3 2023 + Operating income (loss)Q2 2023 + Operating income (loss)Q1 2023 + Operating income (loss)Q4 2022) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

5 Click competitor name to see calculations.


The analyzed financial data reveals several key trends over the given time periods.

Share Price

The share price exhibited a general upward trend from March 2018 to June 2021, increasing from $18.58 to a peak of $142.58. This growth was marked with some fluctuations; a notable surge occurred between December 2019 and June 2020 as the price rose from $63.05 to $104.45. Following the peak in September 2021 at $142.58, the share price declined substantially to $81.09 by September 2023, indicating increased volatility and a downward correction in the more recent periods.

Operating Profit per Share (OPPS)

Operating profit per share was initially negative and only reported starting in December 2018, reflecting initial operational losses. The metric showed steady improvement over time, shifting from -$0.52 in December 2018 to a positive $1.31 by September 2023. This consistent upward trajectory suggests ongoing enhancement in operational efficiency and profitability at the per-share level. Notably, the improvement was gradual with slight deceleration during 2022 before resuming growth in early 2023.

Price to Operating Profit Ratio (P/OP)

The P/OP ratio data, available from March 2020 onward, indicates high valuation multiples throughout the period. Ratios fluctuated mostly between approximately 105 and 155, showing varying investor expectations or market valuation of the company’s operating profitability. A significant decrease occurred in the last two observed quarters, dropping sharply to 61.89 by September 2023, correlating with both the reduced share price and increased operating profit per share. This decline in the P/OP ratio may indicate that the market began to price the company’s earnings more conservatively, or that improved earnings outpaced the decline in share price.

In summary, the data reflects a company that transitioned from operational losses toward sustained positive profitability per share over the analyzed period. The share price generally increased alongside improving earnings but has experienced notable declines in the most recent quarters. The valuation multiples remained elevated for much of the period but have decreased recently, potentially aligning market valuation more closely with actual operating performance.


Price to Sales (P/S)

DexCom Inc., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1
Selected Financial Data (US$)
Revenue (in thousands)
Sales per share2
Share price1, 3
Valuation Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
Sales per share = (RevenueQ3 2023 + RevenueQ2 2023 + RevenueQ1 2023 + RevenueQ4 2022) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

5 Click competitor name to see calculations.


Share Price Trend
The share price exhibited a general upward trend from March 2018 to June 2021, increasing from $18.58 to a peak of $142.58 in September 2021. During this period, the price experienced notable increments, particularly between December 2019 and June 2021. After reaching the peak, the share price declined significantly to $81.09 by September 2023, indicating heightened volatility and a downward adjustment in the most recent quarters.
Sales Per Share Trend
Sales per share data starts from March 2019, showing a steady and consistent increase over the subsequent periods. The figure rose from $2.87 to $8.81 by September 2023, demonstrating continuous growth in sales performance per share. This consistent upward trajectory suggests improving sales efficiency or expansion in revenue generation relative to the number of shares outstanding.
Price to Sales (P/S) Ratio Analysis
The P/S ratio shows pronounced fluctuations across the reporting periods. Initially recorded at 12.76 in March 2019, it decreased to 9.58 in June 2019 before reaching a high point of 23.83 by December 2021. Post this peak, the ratio declined to 9.21 by September 2023. The fluctuations in the P/S ratio reflect changes in market valuation sentiment relative to sales, with the higher values indicating periods when the share price grew faster than sales per share. The recent decline indicates a relative compression of market valuation or an increase in sales growth outpacing the share price increase.
Relationship Between Share Price and Sales Per Share
While both share price and sales per share exhibit growth over the medium term, the share price experienced higher volatility and a larger percentage increase followed by a significant correction, unlike the steadier rise in sales per share. This indicates that market pricing may have become somewhat detached from underlying sales performance during peak periods, before a realignment occurred in the recent quarters.
Summary
The financial data highlights continuous growth in sales per share, suggesting improving business performance. However, the share price, while generally upward trending over the long term, showed considerable volatility and recent decline. The P/S ratio’s fluctuation emphasizes changing market valuation dynamics, with periods of premium valuation relative to sales followed by corrections. Overall, the data suggests an improving fundamental sales performance with price-to-sales valuation experiencing cyclical variations influenced by market conditions.

Price to Book Value (P/BV)

DexCom Inc., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
No. shares of common stock outstanding1
Selected Financial Data (US$)
Stockholders’ equity (in thousands)
Book value per share (BVPS)2
Share price1, 3
Valuation Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2023 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.

4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

5 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several key trends related to the share price, book value per share (BVPS), and price-to-book value ratio (P/BV) over the observed periods.

Share Price
The share price exhibited significant volatility throughout the timeline. Initially, it rose steadily from $18.58 at the end of Q1 2018 to peak at $63.05 in Q4 2019. This was followed by a remarkable increase reaching an all-time high of around $142.58 in Q3 2021. Subsequent quarters showed a notable decline and fluctuations, with the price dropping to $81.09 by Q3 2023. Overall, share price demonstrated periods of robust growth interspersed with corrections and volatility in recent quarters.
Book Value Per Share (BVPS)
The BVPS displayed an upward trend, increasing consistently over the entire period. Starting from $1.20 in Q1 2018, it rose steadily to $5.87 by Q3 2023. The growth in book value per share was particularly notable between Q4 2019 and Q4 2020, where it jumped from $2.41 to $4.75, reflecting underlying asset or equity value increases. In later periods, the BVPS growth decelerated somewhat but remained positive, suggesting stable reinforcement of shareholder equity.
Price-to-Book Value Ratio (P/BV)
The P/BV ratio showed considerable variation reflecting changes in market valuation relative to book value. Starting at around 15.52 in Q1 2018, the ratio peaked at 30.98 in Q1 2020, indicating strong market optimism or potentially overvaluation at that time. Subsequently, the ratio underwent declines and rebounds, with values oscillating between approximately 13.82 and 26.17 in later periods. The P/BV ratio’s recent decline to 13.82 in Q3 2023 suggests a repositioning of the market's valuation of the company relative to its book value, potentially signaling more conservative investor sentiment or realignment with fundamental values.

In summary, the financial data reveal strong growth in both share price and book value per share over the analysis period, albeit with considerable share price volatility. The price-to-book ratio’s fluctuations highlight varying market perceptions, with periods of both elevated optimism and later recalibration towards more moderate valuations. The combination of consistent increases in book value and share price volatility may reflect both operational performance and broader market dynamics affecting investor sentiment.